Nanostructured bacterial materials for innovative medicines

被引:81
|
作者
Rodriguez-Carmona, Escarlata [1 ,2 ,3 ]
Villaverde, Antonio [1 ,2 ,3 ]
机构
[1] Univ Autonoma Barcelona, Inst Biotechnol & Biomed, E-08193 Barcelona, Spain
[2] Univ Autonoma Barcelona, Dept Genet & Microbiol, E-08193 Barcelona, Spain
[3] CIBER Bioingn Biomat & Nanomed CIBER BBN, Zaragoza, Spain
关键词
CADMIUM-SULFIDE NANOPARTICLES; DRUG-DELIVERY SYSTEMS; VIRUS-LIKE PARTICLES; MAGNETOSPIRILLUM-GRYPHISWALDENSE; ESCHERICHIA-COLI; CELL-PROLIFERATION; MAGNETIC PARTICLES; INCLUSION-BODIES; BIOSYNTHESIS; NANOWIRES;
D O I
10.1016/j.tim.2010.06.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The development of innovative medicines and personalized biomedical approaches require the identification and implementation of new biocompatible materials produced by methodologically simple and cheap fabrication methods. The biological fabrication of materials, mostly carried out by microorganisms, has historically provided organic compounds with wide-spectrum biomedical applications, including hyaluronic acid, poly(gamma-glutamic acid) and polyhydroxyalkanoates. Additionally, the implementation of new methodological platforms such as metabolic engineering and systems biology have facilitated the controlled production of natural nanoparticles produced by bacteria, including metallic deposits of Au, Ag, Cd, Zn or Fe, virus-like particles or other nanoscale protein-only entities. The unexpected potential of such self-organized and functional materials in nanomedical scenarios (especially in drug delivery, imaging and tissue engineering) prompts serious consideration of further exploitation of bacterial cell factories as convenient alternatives to chemical synthesis and as sources of novel bioproducts that could dramatically expand the existing catalog of biomedical materials.
引用
收藏
页码:423 / 430
页数:8
相关论文
共 50 条
  • [31] European Technology Platform on Innovative Medicines
    Donnelly, Fergal
    Jehenson, Philippe
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL MEDICINE, 2005, 19 (03): : 153 - 161
  • [32] Product patents and access to innovative medicines
    Dai, Rong
    Watal, Jayashree
    SOCIAL SCIENCE & MEDICINE, 2021, 291
  • [33] An innovative approach to integrated medicines management
    Scullin, Claire
    Scott, Michael G.
    Hogg, Anita
    McElnay, James C.
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2007, 13 (05) : 781 - 788
  • [34] Johnson & Johnson: Innovative medicines & technologies
    Stoffels, Paul
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [35] Impediments to the diffusion of innovative medicines in Europe
    Oliver Schöffski
    PharmacoEconomics, 2004, 22 : 51 - 64
  • [36] Erratum: Reflections on the Innovative Medicines Initiative
    Michel Goldman
    Nature Reviews Drug Discovery, 2011, 10 : 471 - 471
  • [37] Impediments to the diffusion of innovative medicines in Europe
    Schöffski, O
    PHARMACOECONOMICS, 2004, 22 (Suppl 2) : 51 - 64
  • [38] MPs pass innovative medicines bill
    Dyer, Clare
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 352
  • [39] Access to innovative medicines in Europe: An overview
    Sekulovic, L. K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 31 - 31
  • [40] Antimicrobial peptides: an alternative for innovative medicines?
    da Costa, Joao Pinto
    Cova, Marta
    Ferreira, Rita
    Vitorino, Rui
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2015, 99 (05) : 2023 - 2040